top of page

AMR issues from cystitis treatments

From our Chief Medical Director, Professor Scott Glickman:

With people working on AMR from cystitis treatments, I would be grateful to discuss the following conundrum.

My analysis indicates that the oral/systemic route of administration is critically flawed by rate-limited initial drug filtration and ureteric drip-feed of antibiotic into urinary pools of sufficient volumes to delay it reaching MIC, and with its fluctuant pH likely dynamically altering MIC in-vivo as well, thus potentially providing a window of opportunity for bacteria to react in defence before therapeutic threshold is reached, but haven't determined if it can be tested experimentally, because there are too many uncontrollable variables.

Does anybody have any helpful ideas or is modelling the only option?

You can follow this thread in UroPharma's LinkedIn page

2 views0 comments

Recent Posts

See All

The urobiome

Following on from revelations that we have a complex symbiotic relationship with our #gut microbiome, the discovery that we also have a #urobiome has attracted much attention. There’s no going back to

"We know almost nothing about managing UTI"

“We know almost nothing about managing UTI.” This assertion went unchallenged at the British Society of #Antimicrobial Chemotherapy multidisciplinary conference of experts last year. Increasingly, we

GAG-layer supplements

From Prof. Scott Glickman: A GAG (#glycosaminoglycan) layer within the #bladder, as a nanometres-thick coating, surely would be less than 2ml. Why do companies sell costly GAG-layer supplements as 50m

bottom of page